Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.

Rui-Hua XuLin ShenKe-Ming WangGang WuChun-Mei ShiKe-Feng DingLi-Zhu LinJin-Wan WangJian-Ping XiongChang-Ping WuJin LiYun-Peng LiuDong WangYi BaJue-Ping FengYu-Xian BaiJing-Wang BiLi-Wen MaJian LeiQing YangHao Yu

Published in: Chinese journal of cancer (2017)

Famitinib prolonged PFS in refractory mCRC patients with acceptable tolerability. Trial registration This study was registered on ClinicalTrials.gov (NCT01762293) and was orally presented in the 2015 ASCO-Gastrointestinal Symposium.

Keyphrases

phase ii
placebo controlled
double blind
clinical trial
phase iii
metastatic colorectal cancer
open label
study protocol
phase ii study
randomized controlled trial
cross sectional
combination therapy
replacement therapy